Clinical trial
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as…
NCT03217838 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT03217838 |
|---|---|
| Title | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. |
| Official title | A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukaemia |
| Intervention type | Drug |
| Interventions | AZD2811, Azacitidine, Venetoclax |
| Enrollment | 50 |
| Start date | Jul 31, 2017 |
| Primary completion | Mar 25, 2021 |
| Completion | Mar 25, 2021 |
| First posted | Jul 14, 2017 |
| Last update posted | Apr 5, 2022 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: